The effect of serotonin reuptake inhibitors on the vaginal epithelium in postmenopausal women

References

• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–9
   PubMed Web of Science ®Google Scholar
• Nunez-Pizarro JL, Gonzalez-Luna A, Mezones-Holquin E, et al. Association between anxiety and severe quality-of-life impairment in postmenopausal women: analysis of a multicenter Latin American cross-sectional study. Menopause 2017;24:645–52
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N. and International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
   PubMed Web of Science ®Google Scholar
• Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155–72
   PubMed Web of Science ®Google Scholar
• Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–13
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Grigoriadis S, et al. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 2005;172:57–59
   PubMed Web of Science ®Google Scholar
• Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959–65
   PubMed Web of Science ®Google Scholar
• Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27–32
   PubMed Web of Science ®Google Scholar
• Chua Y, Limpaphayom KK, Cheng B, et al. Genitourinary syndrome of menopause in five Asian countries: results from the Pan-Asian REVIVE survey. Climacteric 2017;20:367–73
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 2016;19:188–97
   PubMed Web of Science ®Google Scholar
• Reed SD, Guthrie KA, Joffe H, et al. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012;119:527–38
   PubMed Web of Science ®Google Scholar
• Reed SD, Mitchell CM, Joffe H, et al. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014;124:233–41
   PubMed Web of Science ®Google Scholar
• Caan B, LaCroix AZ, Joffe H, et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause 2015;22:607–15
   PubMed Web of Science ®Google Scholar
• Thompson IOC, van der Bijl P, van Wyk CW, et al. A comparative light-microscopic, electron-microscopic and chemical study of human vaginal and buccal epithelium. Arch Oral Biol 2001;46:1091–8
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208
   PubMed Web of Science ®Google Scholar
• van der Laak JAWM, de Bie LMT, de Leeuw H, et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol 2002;55:446–51
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Pacher P, Koller A. Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i. J Cardiovasc Pharmacol 2000;35:849–54
   PubMed Web of Science ®Google Scholar
• Saha PR, Alsip NL, Henzel MK, et al. Role of nitric oxide and cyclooxygenase products in controlling vascular tone in uterine microvessels of rats. J Reprod Fertil 1998;112:211–16
   PubMedGoogle Scholar
• Echeverry MC, Arango A, Castro B, et al. Study of the prevalence of female sexual dysfunction in sexually active women 18 to 40 years of age in Medellin, Colombia. J Sex Med 2010;7:2663–9
   PubMed Web of Science ®Google Scholar
• Midi M, Kanagasundram S, Sidi H, et al. Sexual arousal difficulties in women treated with antidepressants: a comparison between escitalopram and fluoxetine. Int J Psychiatry Med 2012;43:405–18
   PubMed Web of Science ®Google Scholar
• Clayton A, Kornstein S, Prakash A, et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917–29
   PubMed Web of Science ®Google Scholar
• Portman DJ, Kaunitz AM, Kazempour K, et al. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause 2014;21:1082–90
   PubMed Web of Science ®Google Scholar